** Shares of Stoke Therapeutics STOK.O rise 12.6% to $12.88
** The biotech says it has received U.S. FDA's "breakthrough therapy designation" for zorevunersen, its experimental drug for epileptic disorder Dravet Syndrome
** The FDA's tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need
** Breakthrough designation seems appropriate given disease modifying potential in a field of symptomatic treatments, brokerage BTIG says
** If approved, the drug could become the first disease modifying treatment for the disease
** Including session's moves, stock up 143.54% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.